Curcumin Synergizes with Cisplatin to Inhibit Colon Cancer through Targeting the MicroRNA-137-Glutaminase Axis

Abstract

Objective

Colorectal cancer (CRC) is one of the most lethal and prevalent malignancies world-wide. Currently, surgery, radiotherapy and chemotherapy are clinically applied as common approaches for CRC patients. Cisplatin is one of the most frequently used chemotherapy drugs for diverse cancers. Although chemotherapeutic strategies have improved the prognosis and survival of cancer patients, development of cisplatin resistance has led to cancer recurrence. Curcumin, isolated from turmeric, has been used as an effective anti-cancer agent. However, the molecular mechanisms for curcumin-mediated cisplatin sensitivity of CRC have not been elucidated. This study aimed to investigate the effects of curcumin treatment on cisplatin-resistant CRC cells.

Methods

Expression levels of miRNAs and mRNAs were determined by qRT-PCR. Protein expression levels were detected by Western blotting. Cell responses to curcumin treatments were evaluated by MTT assay, Clonogenic assay and Annexin V apoptosis assay. The glutamine metabolism of colon cancer cells was assessed by glutamine uptake and glutaminase (GLS) activity. The binding of miR-137 on 3′ UTR of GLS was validated by Western blotting and luciferase assay.

Results

Results demonstrated that curcumin significantly synergized with cisplatin (combination index <1) to suppress proliferation of colon cancer cells compared with curcumin or cisplatin alone. Moreover, from the established cisplatin-resistant cell line (HT-29), glutamine metabolism was remarkedly elevated in cisplatin-resistant CRC cells that displayed a glutamine addictive phenotype. Furthermore, curcumin treatments attenuated glutamine metabolism in colon cancer cells. Under low glutamine supply, colon cancer cells showed less sensitivity to curcumin. Using a microRNA (miRNA) microArray assay, miR-137, a tumor suppressor in colon cancer, was significantly induced by curcumin treatments in CRC cells. Bioinformatics analysis and a luciferase assay illustrated miR-137 directly targeted the 3′ UTR of GLS mRNA. Rescue experiments demonstrated that miR-137-induced cisplatin sensitization was through targeting of GLS. Finally, curcumin treatment overcame cisplatin resistance through miR-137-mediated glutamine inhibition.

Conclusion

Collectively, these results indicate that curcumin could be clinically applied as an anti-chemoresistance approach against CRC by modulating miR-137-inhibited glutamine metabolism.

Keywords

glutamine metabolism / microRNA-137 / curcumin / cisplatin resistant / glutaminase

References

[1] DekkerE, TanisPJ, VleugelsJLA, et al.. Colorectal cancer. Lancet, 2019, 394(10207): 1467-1480

[2] WuC. Systemic Therapy for Colon Cancer. Surg Oncol Clin N Am, 2018, 27(2): 235-242

[3] DasariS, TchounwouPB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol, 2014, 740: 364-378

[4] GalluzziL, SenovillaL, VitaleI, et al.. Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31(15): 1869-1883

[5] GiordanoA, TommonaroG. Curcumin and Cancer. Nutrients, 2019, 11(10): 2376

[6] AdiwidjajaJ, McLachlanAJ, BoddyAV. Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions. Expert Opin Drug Metab Toxicol, 2017, 13(9): 953-972

[7] AgarwalA, KasinathanA, GanesanR, et al.. Curcumin induces apoptosis and cell cycle arrest via the activation of reactive oxygen species-independent mitochondrial apoptotic pathway in Smad4 and p53 mutated colon adenocarcinoma HT29 cells. Nutr Res, 2018, 51: 67-81

[8] MortezaeeK, SalehiE, Mirtavoos-MahyariH, et al.. Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy. J Cell Physiol, 2019, 234(8): 12537-12550

[9] MarquardtJU, Gomez-QuirozL, Arreguin CamachoLO, et al.. Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer. J Hepatol, 2015, 63(3): 661-669

[10] MirzaeiH, MasoudifarA, SahebkarA, et al.. MicroRNA: A novel target of curcumin in cancer therapy. J Cell Physiol, 2018, 233(4): 3004-3015

[11] LiuJ, LiM, WangY, et al.. Curcumin sensitizes prostate cancer cells to radiation partly via epigenetic activation of miR-143 and miR-143 mediated autophagy inhibition. J Drug Target, 2017, 25(7): 645-652

[12] SalehiB, Stojanović-RadićZ, MatejićJ, et al.. The therapeutic potential of curcumin: A review of clinical trials. Eur J Med Chem, 2019, 163: 527-545

[13] CluntunAA, LukeyMJ, CerioneRA, et al.. Glutamine Metabolism in Cancer: Understanding the Heterogeneity. Trends Cancer, 2017, 3(3): 169-180

[14] YangL, VennetiS, NagrathD. Glutaminolysis: A Hallmark of Cancer Metabolism. Annu Rev Biomed Eng, 2017, 19: 163-194

[15] ChenR, LaiLA, SullivanY, et al.. Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer. Sci Rep, 2017, 7(1): 7950

[16] ChouTC. Preclinical versus clinical drug combination studies. Leuk Lymphoma, 2008, 49(11): 2059-2080

[17] VerduciL, StranoS, YardenY, et al.. The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment. Mol Oncol, 2019, 13(4): 669-680

[18] KimJH, LeeKJ, SeoY, et al.. Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism. Sci Rep, 2018, 8(1): 409

[19] WangY, ChenR, ZhouX, et al.. miR-137: A Novel Therapeutic Target for Human Glioma. Mol Ther Nucleic Acids, 2020, 21: 614-622

[20] BiWP, XiaM, WangXJ. miR-137 suppresses proliferation, migration and invasion of colon cancer cell lines by targeting TCF4. Oncol Lett, 2018, 15(6): 8744-8748

[21] LuoM, WuL, ZhangK, et al.. miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. Cell Death Differ, 2018, 25(8): 1457-1472

[22] HuangZM, YangJ, ShenXY, et al.. MicroRNA expression profile in non-cancerous colonic tissue associated with lymph node metastasis of colon cancer. J Dig Dis, 2009, 10(3): 188-194

[23] LuanW, ZhouZ, ZhuY, et al.. miR-137 inhibits glutamine catabolism and growth of malignant melanoma by targeting glutaminase. Biochem Biophys Res Commun, 2018, 495(1): 46-52